These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7695976)

  • 1. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
    Kataja V; Yap A
    Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer.
    Chao TY; Hwang WS; Yang MJ; Chang JY; Wang CC; Hseuh EJ; Huang SH; Chen WC
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Oct; 56(4):232-8. PubMed ID: 8548664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
    Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V
    Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
    Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
    Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancer.
    Hastürk S; Kurt B; Kocabaş A; Nadirler F; Orüc O
    Cancer Lett; 1997 Jan; 112(1):17-22. PubMed ID: 9029165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
    Kelly K; Crowley JJ; Bunn PA; Hazuka MB; Beasley K; Upchurch C; Weiss GR; Hicks WJ; Gandara DR; Rivkin S
    J Clin Oncol; 1995 Dec; 13(12):2924-30. PubMed ID: 8523056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
    Halme M; Maasilta PK; Pyrhönen SO; Mattson KV
    Eur J Cancer; 1994; 30A(1):11-5. PubMed ID: 8142151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
    Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.